Dyadic International, Inc. Receives C1 Derived Vaccine Test Results From Sanofi Pasteur And Provides Further Details On New EU-Funded ZAPI Biopharmaceutical Program
JUPITER, Fla., Oct. 07, 2015 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the biopharmaceutical, bioenergy, bio-based chemicals, food and feed industries, announced today it has received the test results from the mice trials in our research program with Sanofi Pasteur. The data generated by Sanofi Pasteur indicates that the C1 produced antigen generated an equal, or better, immune response in mice than the industry standard antigen.
"We are very encouraged by these results and remain optimistic as to the potential benefits our C1 technology can bring to the biopharmaceutical industry. We believe our C1 Expression System has the potential to aid in the discovery, development and manufacture of new, better and more affordable human and animal vaccines, antibodies, biosimilars and other therapeutic proteins," said Dyadic’s founder & CEO, Mark Emalfarb. "Our expansion into biopharmaceutical’s is taking shape. With the promising Sanofi results and our participation in the EU funded Zoonoses Anticipation and Preparedness Initiative or ZAPI, which was launched earlier this year, we expect to further develop our capabilities and establish our C1 Technology as a competitive manufacturing platform for use in producing novel, and low cost vaccines, biosimilars and other biologics."
The ZAPI initiative, sponsored by the EU Horizon 2020 program, brings together and will draw upon leading human and animal health expertise across Europe. The objective of the program is to develop an end-to-end solution for the rapid development, production, regulatory approval and launch of vaccine products to combat epidemic infectious diseases in animals that have the potential to effect the human population. Led by Merial, Sanofi’s animal health arm, participants within ZAPI include experts from regulatory agencies, academia and industry including AstraZeneca, Utrecht University, University of Bonn, Leiden University and a number of small and medium enterprises (SMEs). We believe that Dyadic’s C1 technology may play a key role in ZAPI as a core enabling technology in a rapid product development and production system.
To learn more about the EU Horizon 2020 ZAPI program go to the following link:
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic’s ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic’s research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel, (6) Dyadic’s ability to obtain additional debt or equity financing sources and (7) other many other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in our December 31, 2014 Annual Report filed with OTC Markets on March 27, 2015.
Contact: Dyadic International, Inc. Mark Emalfarb Chief Executive Officer Phone: 561-743-8333 Email: firstname.lastname@example.org and post your resume.